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Abstract
Background: A simple method to estimate CD4 counts in stable, HIV infected virologically-suppressed and
immune-reconstituted adults could save the expense of unnecessary formal testing.
Methods: Using a baseline CD4 percent, CD4 counts were estimated from subsequent absolute lymphocyte counts
(ALC) measured by an automated FBC machine (CD4 estimate calculated by the ALC multiplied by the baseline
CD4 percent). The accuracy of this approach was established in a large, retrospective clinical laboratory dataset of
virologically-suppressed HIV infected subjects. A case–control study explored important clinical factors for accurate
estimates, and a heuristic algorithm was derived and validated in a random sample.
Results: Data from 3,630 subjects were available. CD4 counts were generally accurately estimated, with a
mean 6.1 % underestimation. Overall 83.3 % of CD4 estimates were within 25 % of the actual values, with
12.1 % CD4 counts underestimated by more than 25 %, and 4.5 % overestimated. The CD4 count was
increasingly underestimated with time from baseline, and the degree of underestimation correlated with
baseline CD4 percent (p < 0.0001). From the case–control study, baseline CD4 percent of ≥20, no illness
requiring hospitalization and more than a year since starting or switch of anti-retroviral therapy were identified as
significant predictors of inaccurate estimates. Employing this simple algorithm, CD4 estimate accuracy improved to a
mean 1.3 % underestimation, and the proportion of estimates within 25 % of the actual value increased to 93.4 %.
Conclusions: In virologically-suppressed and immune-reconstituted HIV-infected adults, the CD4 count can be
accurately estimated from the ALC using a baseline CD4 percent for at least 2 years after measurement.
Background
The clinical value of routinely monitoring CD4 counts in
HIV-infected adults with virologic suppression and im-
mune reconstitution is questionable. After counts have
risen to more than 300–350 cells/mm3, the proportion
subsequently falling to less than 200 cells/mm3 is reported
as only 1.1–2.9 % in retrospective studies [1–4]. The
majority of these declines are predictable, transient, not
directly due to HIV or anti-retroviral therapy (ART) and
do not increase the risk of opportunistic infections.
Reducing the frequency of CD4 testing has the poten-
tial for substantial cost savings - estimated at up to $18.1
million per year in the US [5]. Based on these findings, re-
cent guidelines from the International AIDS Society (IAS)
have recommended that among virologically suppressed
individuals with CD4 counts above 500 cells/mm3 further
monitoring of CD4 counts is optional [6]. Yet while
patients may feel anxious over clinically insignificant
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fluctuations in the CD4 count, resistance to reduced mon-
itoring has also been suggested.
We hypothesised that following virologic suppression
and immune reconstitution, CD4 counts could be esti-
mated using lymphocyte measurements from an auto-
mated full blood count (FBC) analyser. Such a method
has not, to our knowledge, been reported before. FBCs
are an important part of routine HIV care regardless of
disease stage. In a retrospective cohort study, we aimed
to derive and validate a simple heuristic algorithm that
is able to estimate CD4 counts reliably.
Methods
All available HIV viral loads (VL) and CD4 panels (in-
cluding CD4/8 absolute values, percent and lymphocyte
counts) were extracted from an electronic laboratory
database. Where at least one CD4 or VL was available
for a subject, absolute lymphocyte counts (ALCs) from
FBC measurements were also extracted. Data was avail-
able from January 2008 to September 2013. CD4 panels
were performed on a flow cytometer (BD Biosciences,
New Jersey, USA), while FBC results were from an auto-
mated analyser (Beckman Coulter, California, USA). No
patient information was available from this database.
Periods of virologic suppression were identified. Viro-
logic suppression was defined as at least two consecutive
viral loads less than 200 copies/ml within 400 days of
each other, similar to other studies. During each period
of virologic suppression, the first absolute CD4 measure-
ment greater than 300 cells/mm3 and the accompanying
CD4 percent was identified and used as baseline. For the
following 720 days, CD4 and ALC measurements taken
on the same day were collected. The baseline CD4 per-
cent was used to estimate an absolute CD4 count from
subsequent ALCs (CD4 estimate = ALC x baseline CD4
percent). Estimated CD4 values were compared with the
actual value for accuracy (predicted CD4/actual CD4 x
100). Two factors were chosen as clinically relevant
markers of accuracy:
1. Proportion of CD4 estimates within 10 % and 25 %
of the actual value
2. Percentage deviation of accuracy from zero covering
90 % of estimates
Actual CD4 values less than 200 cells/mm3 were identi-
fied. Electronic and paper patient records were reviewed
to determine if a cause could be identified – including
serious illness requiring hospital admission within one
month before CD4 measurement, cytotoxic chemo-
therapy, hepatitis C treatment or any other expected
cause of lymphopenia.
A case–control study (1:2) of 150 individuals was then
performed to identify factors predicting inaccurate
results. Cases were defined as greater than 25 % under-
estimation of the actual CD4 value, while controls as es-
timates within 25 %.
Cases and controls were matched by expected con-
founders: baseline CD4 percent (exact) and days from
baseline to CD4 estimate (within 28 days). Cases and
controls were sampled randomly without replacement,
each subject contributing only one estimate. Electronic
and paper records were reviewed and compared for
demographics, history of AIDS-defining infections, trough
CD4 less than 200 cells/mm3, ART regimen and serious
illnesses within one month prior to the date of CD4 or
ALC testing.
Results from the case–control study were used to de-
termine simple baseline clinical requirements which
were predictive of accurate CD4 estimates. The algo-
rithm was validated in a sample of 100 individuals by
reviewing electronic and paper records. Where possible
new CD4 estimates were generated when baseline clin-
ical conditions were not met. Accuracy of estimates was
compared between the two sets.
Statistical analysis was performed using R [7]. All sam-
ples were assumed to be independent (including for the
case–control study), and p-values were interpreted with
a two-tailed significance level of 5 %.
This study was performed at the Communicable Dis-
ease Centre (CDC), Tan Tock Seng Hospital Singapore.
CDC is the main treatment centre for HIV in Singapore,
with approximately 2,500 patients attending for HIV care
annually. The study was approved by the National
Healthcare Group Domain Specific Review Board, and
access to the database approved by the Head of Infec-
tious Diseases Department, Tan Tock Seng Hospital.
Results
Fifteen thousand seventy-nine HIV VLs and 29,927
CD4 counts were available for analysis from 3,630
subjects. 3,885 paired CD4-ALCs covering 1,444 periods
of virologic suppression in 1,388 subjects met the inclu-
sion criteria for the study. Median frequency of VLs was
175 days (inter-quartile range (IQR): 127–245), median
frequency of CD4 counts was 147 days (IQR: 105–178).
Estimating CD4 values
Overall 83.3 % of CD4 estimates were within 25 % of the
actual values, and 41.3 % within 10 %. 90 % of predicted
CD4 counts were within 30 % of the actual value. Accur-
acy measures approximated the normal distribution with
a mean 6.1 % underestimation. As a result, while 12.1 %
CD4 counts were underestimated by more than 25 %,
only 4.5 % were overestimated.
Lymphocyte counts correlated well between flow
cytometry and automated FBC measurements (r = 0.970,
p < 0.0001). A median absolute difference of 5.5 % was
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observed, but without significant variation of the mean
from zero (one sample t test, p = 0.40). No significant
difference between lymphocyte counts measured by CD4
panel or FBC were identified when results were stratified
by absolute CD4 count or CD4 percent.
The ALC was only moderately correlated with the CD4
count (r = 0.589, p < 0.0001), and correlation with the
CD4% was negative and substantially weaker (r = −0.216,
p < 0.0001). Thus while the ALC is an accurate measure of
lymphocyte counts, its ability to predict the CD4 count is
limited.
As expected, absolute CD4 count and CD4 percent
were significantly higher with increasing time from
baseline measurement (p < 0.0001). CD4 count was in-
creasingly underestimated with time, and the degree
of underestimation correlated with baseline CD4
percent (p < 0.0001). When the baseline CD4 percent
was ≥25, more than 90 % of estimates were within
25 % of the actual value out to 720 days (Fig. 1).
Case–control study
One hundred controls were matched to 50 cases. Case
and controls were well matched by CD4 percent baseline
and days (Table 1).
No significant differences in baseline lymphocyte
counts, absolute CD4, CD8 or CD4/8 ratio were identi-
fied between cases and controls. There was also no sig-
nificant difference between lymphocyte measurements
by FBC and flow cytometry.
Controls had a significantly smaller increase in CD4
percent from baseline to estimate (p < 0.0001), and sig-
nificantly lower CD4 counts (p = 0.002). Stable CD4 per-
cent with time is clearly important for accurate results,
and stability was not affected by age, gender, history of
AIDS-defining illnesses or a documented CD4 trough of
less than 200 cells/mm3. However, presence of serious
illness requiring hospital admission predicted inaccurate
estimates (p = 0.0001), as did less than a year since start-
ing ART (p = 0.035). Change of ART in virologically sup-
pressed hosts was common and more frequent among
cases, but this rate were not statistically significantly dif-
ferent from controls. 15/17 (88.2 %) of switches were be-
tween nucleoside reverse transcriptase inhibitors,
primarily from stavudine to zidovudine or tenofovir.
Heuristic algorithm and validation
The following baseline parameters for CD4 estimates
were chosen for the validation phase of the study:
1. Baseline CD4 percent ≥20, Absolute CD4 ≥ 300
2. Virologic suppression (<200 copies/ml)
3. More than one year since starting ART or a change
in regimen
4. No serious concomitant illness requiring hospital
admission or expected to cause lymphopenia
A new sample of 100 individuals was screened fol-
lowing the above algorithm, yielding 292 CD4 esti-
mates. 5 subjects were excluded from validation as no
results where available meeting baseline criteria, while
49 subjects required recalculation of estimates. Primary
reasons for recalculation were ART related – treatment
for less than one year in 28 (51.9 %) and switch of therapy
in 22 (40.7 %). 243 CD4 estimates were analysed after val-
idation. There was no statistically significant difference in
the average time since baseline CD4% in either group
Fig. 1 Accuracy of CD4 estimates as a function of time and stratified by baseline CD4 percent. ‘Overall’ includes all results
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(derivation 352 days vs. validation 359 days), while mean
baseline CD4 percent increased marginally from 25.4 to
26.8 % (p = 0.002, t-test).
The algorithm significantly improved accuracy of CD4
estimates. The proportion of estimates within 25 % of
the actual value increased from 86.0 to 93.4 % (p = 0.007),
and within 10 % from 46.6 to 57.2 % (p = 0.015). 90 % con-
fidence intervals for estimates narrowed from 28 to 22 %.
Estimates were significantly more accurate in the first
versus second year for the derivation cohort (mean
1.8 % vs. 6.2 % underestimation, p = 0.044). This nar-
rowed after validation (mean 0 % v 4.7 % underestima-
tion, p = 0.002).
CD4 dips to less than 200 cell/mm3
From the initial cohort, 49 (1.3 %) CD4 counts from 41
subjects were less than 200 cells/mm3. 34 (69.3 %) were
identified in the first year of care. 31/49 of these were
also predicted by the algorithm (sensitivity 63.3 %, 95 %
CI: 48.3–76.6; specificity 98.8 %, 95 % CI 98.4–99.1).
After reviewing the charts of the 41 subjects, serious ill-
nesses were identified in 10. CD4 dips were typically
transient, in only 6 of 39 subjects (15.4 %) with follow
up CD4 counts were dips below 200 cells/mm3 sustained
for more than one CD4 measurement. No AIDS-
defining opportunistic infections were diagnosed when
the CD4 count was less than 200 cells/mm3.
Discussion
In immune-reconstituted, virologically suppressed and
clinically stable HIV-infected adults, the CD4 count can
be accurately estimated by multiplying the absolute
lymphocyte count by a baseline CD4 percent. This esti-
mate is within 25 % of the actual value almost 95 % of
the time for at least the first two years from baseline
measurement.
Previous studies have demonstrated that using ALC cut-
offs to predict an absolute CD4 count of <200 cells/mm3
or response to ART is unreliable for clinical use [7, 8].
The primary reason for this lack of concordance between
ALC and CD4 is variability in the CD4 percent rather than
large discrepancies between lymphocyte counts when
measured by an automated FBC analyser or lymphocyte
subset flow cytometer. Stability of the CD4 percent is cru-
cial for accurate CD4 estimates using the method outlined
here. The CD4 percent has less physiological variability
than the absolute count, and following immune reconsti-
tution increases in the CD4 percentage are proportionally
smaller [9].
Data from this study supports reducing the frequency
of CD4 monitoring in clinically stable, virologically-
suppressed and immune-reconstituted adults. Similar to
previous studies, the proportion of CD4 values less than
200 cells/mm3 was low – only 1.3 % and was generally
predictable, transient and not associated with opportun-
istic infections. The clinical utility of CD4 counts in this
population is limited, yet, measurement continues. We
propose that where patients or healthcare providers pre-
fer knowing a CD4 value, this study provides a simple
and accurate method of estimating it. The reassurance
of this estimate may facilitate implementation of recent
guidelines to reduce the frequency of testing and achieve
anticipated cost savings. At our institution, CD4 panels
are substantially more expensive than FBC counts
(113.42 vs 25.74 SGD, before government subsidies). For
the 100 patients in the validation phase of this study,
stopping CD4 counts was equivalent to a cost saving of
$27,561 over two years.
This study has several limitations. It is retrospective
and was performed in a population that was largely male
with a low incidence of intravenous drug use and hepa-
titis C infection (2 %) [10]. Zidovudine or stavudine-
based anti-retroviral therapy were standard first line
treatments until recently, and the association of these
agents with lymphopenia may reduce the accuracy of
this method. A VL periodicity of 400 days was chosen to
reflect local clinical practice, where annual testing is
sometimes necessary due to cost considerations. Inevitably
this does not guarantee continuous virologic suppression.
Treatment interruptions which were unrecognised or not
confirmed virologically were not excluded from this ana-
lysis. The number of CD4 estimates per individual was
not restricted. However, more frequent monitoring is
more likely during periods of clinical instability or early
during the treatment course. Both limitations are likely to






Baseline CD4% (mean) 19 19 NSa
Days from baseline CD4%
to estimated CD4 (mean)
393 393 NSa
Mean age (years) 45 47 NSa
Proportion >50 years 34 % 38 % 0.85 (0.46–1.55), NSb
Sex (male) 90 % 90 % 1 (0.35–2.84), NSb
History of AIDS defining
illness or trough CD4 < 200
62 % 66 % 0.83 (0.44–1.57), NSb
First line ART 84 % 88 % 0.71 (0.28–1.73), NSb
Days ART (mean) 795 1004 NSa
<180 days 38 % 21 % 2.30 (1.09–4.87), 0.032b
<360 days 50 % 32 % 2.12 (1.06–4.26), 0.035b
<720 days 62 % 45 % 1.99 (1.00–3.99), 0.058b
ART switch (not due to
virologic failure)
18 % 8 % 2.52 (0.91–7.01), 0.1 b
Illness 16 % 0 % 0.0001 b
astudents t test, bChi square, Fischer’s exact
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bias this study towards inaccurate CD4 estimates and are
mitigated by the validation phase.
An estimated CD4 count within 25 % of the actual
value was chosen a priori as clinically adequate. What
degree of accuracy is acceptable is debatable, but this
level is similar to expected physiological variability [9,
11]. Finally, a single set of simple clinical rules was
chosen for validation in a relatively small cohort which
may not have been representative. These rules may not
be the best possible for accurate CD4 estimates.
Conclusion
In virologically-suppressed and immune-reconstituted
HIV-infected adults, the CD4 count can be accurately
estimated from the ALC using a baseline CD4 percent
for at least 2 years after measurement.
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